Article info
PDFReview
Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions
- Correspondence to Michel Michaelides, Moorfields Eye Hospital, London EC1V 9EL, UK; michel.michaelides{at}ucl.ac.uk
Citation
Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions
Publication history
- Received February 27, 2020
- Revised March 18, 2020
- Accepted March 20, 2020
- First published April 8, 2020.
Online issue publication
January 21, 2021
Article Versions
- Previous version (8 April 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.